Emergent BioSolutions Inc.
EBS
$8.71
-$0.49-5.33%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 123.76% | 76.72% | 74.94% | 73.16% | 2.02% |
| Total Depreciation and Amortization | -11.14% | -10.22% | -13.03% | -5.15% | -15.81% |
| Total Amortization of Deferred Charges | -99.14% | -89.71% | -65.26% | -34.34% | 94.17% |
| Total Other Non-Cash Items | -109.46% | -86.05% | -90.71% | -91.15% | 21.88% |
| Change in Net Operating Assets | -119.68% | 151.25% | 226.17% | 316.12% | 364.63% |
| Cash from Operations | 119.48% | 229.68% | 128.45% | 217.24% | 127.54% |
| Capital Expenditure | 64.47% | 66.81% | 55.62% | 48.90% | 50.19% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -59.22% | -59.22% | -59.22% | -100.00% |
| Other Investing Activities | 496.83% | 496.83% | 576.19% | 100.00% | 97.63% |
| Cash from Investing | 575.49% | -9.74% | -41.03% | -52.22% | 38.58% |
| Total Debt Issued | 157.65% | 234.29% | 1,320.00% | -15.56% | -85.79% |
| Total Debt Repaid | -222.15% | 16.03% | 14.38% | 10.38% | 75.42% |
| Issuance of Common Stock | 678.57% | 6.86% | 5.88% | -6.96% | -87.83% |
| Repurchase of Common Stock | -925.00% | -62.50% | 52.00% | 64.29% | 73.33% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 179.66% | -- | -- | -- | -- |
| Cash from Financing | -284.74% | 52.30% | 64.53% | 0.80% | -157.06% |
| Foreign Exchange rate Adjustments | 175.00% | 30.00% | -- | -207.14% | 42.86% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,236.36% | 121.01% | 98.85% | 144.78% | 93.47% |